Literature DB >> 19046847

A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis.

G Houvenaeghel1, C Nos, S Giard, H Mignotte, B Esterni, J Jacquemier, M Buttarelli, J-M Classe, M Cohen, P Rouanet, F Penault Llorca, P Bonnier, F Marchal, J-R Garbay, J Fraisse, P Martel, E Fondrinier, C Tunon de Lara, J-F Rodier.   

Abstract

PURPOSE: Predictive factors of non-sentinel lymph node (NSN) involvement at axillary lymph node dissection (ALND) have been studied in the case of sentinel node (SN) involvement, with validation of a nomogram. This nomogram is not accurate for SN micrometastasis. The purpose of our study was to determine a nomogram for predicting the likelihood of NSN involvement in breast cancer patients with a SN micrometastasis.
METHODS: We collated 909 observations of SN micrometastases with additional ALND. Characteristics of the patients, tumours and SN were analysed.
RESULTS: Involvement of SN was diagnosed 490 times (53.9%) with standard staining (HES) and 419 times solely on immunohistochemical analysis (IHC) (46.1%). NSN invasion was observed in 114 patients (12.5%), whereas 62.3% (71) had only one NSN involved and 37.7% (43) two or more NSN involved. In multivariate analysis, significant predictive factors were: tumour size (pT stage < or = 10 mm or >11 and < or = 20 or >20 mm [odds ratio (OR) 2.1 and 3.43], micrometastases detected by HES or IHC [OR 1.64], presence or absence of lymphovascular invasion (LVI) [OR 1.76], tumour histological type mixed or not [OR 2.64]. The rate and probability of NSN involvement with the model are given for 24 groups, with a representation by a nomogram.
CONCLUSION: One group, corresponding to 10.1% of the patients, was associated with a risk of NSN involvement of less than 5%, and five groups, corresponding to 29.8% of the patients, were associated with a risk < or = 10%. Omission of ALND could be proposed with minimal risk for a low probability of NSN involvement.

Entities:  

Mesh:

Year:  2008        PMID: 19046847     DOI: 10.1016/j.ejso.2008.10.003

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  17 in total

1.  Lymphangiogenesis in breast cancer is associated with non-sentinel lymph node metastases in sentinel node positive patients.

Authors:  Lin Lv; Rui-Min Ma; Fan Yang; Xiao-Hua Zhang; Du-Ping Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  Regional Disease Control in Selected Patients with Sentinel Lymph Node Involvement and Omission of Axillary Lymph Node Dissection.

Authors:  Gábor Cserni; Róbert Maráz
Journal:  Pathol Oncol Res       Date:  2015-02-04       Impact factor: 3.201

3.  Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays.

Authors:  Georg Sauer; Nicole Schneiderhan-Marra; Rainer Muche; Karin Koretz; Cornelia Kazmaier; Rolf Kreienberg; Thomas Joos; Helmut Deissler
Journal:  J Cancer Res Clin Oncol       Date:  2011-04-24       Impact factor: 4.553

4.  Post-operative nomogram for predicting freedom from recurrence after surgery in localised breast cancer receiving adjuvant hormone therapy.

Authors:  Chafika Mazouni; Frédéric Fina; Sylvie Romain; Pascal Bonnier; L'houcine Ouafik; Pierre-Marie Martin
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-30       Impact factor: 4.553

5.  Axillary Lymph Node Status in Early-Stage Breast Cancer Patients with Sentinel Node Micrometastases (0.2-2 mm).

Authors:  Johannes Bargehr; Michael Edlinger; Michael Hubalek; Christian Marth; Roland Reitsamer
Journal:  Breast Care (Basel)       Date:  2013-06       Impact factor: 2.860

Review 6.  Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift.

Authors:  Aoife Maguire; Edi Brogi
Journal:  Arch Pathol Lab Med       Date:  2016-08       Impact factor: 5.534

7.  Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

Authors:  Tracy-Ann Moo; Marcia Edelweiss; Sabina Hajiyeva; Michelle Stempel; Monica Raiss; Emily C Zabor; Andrea Barrio; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2018-03-23       Impact factor: 5.344

Review 8.  Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy.

Authors:  Agnès Tallet; Eric Lambaudie; Monique Cohen; Mathieu Minsat; Marie Bannier; Michel Resbeut; Gilles Houvenaeghel
Journal:  World J Clin Oncol       Date:  2016-04-10

9.  Patients' choice on axillary lymph node dissection following sentinel lymph node micrometastasis--first report on prospective use of a nomogram in very low risk patients.

Authors:  Gábor Cserni; Istvánné Bezsenyi; László Markó
Journal:  Pathol Oncol Res       Date:  2012-10-16       Impact factor: 3.201

Review 10.  Sentinel lymph nodes for breast carcinoma: an update on current practice.

Authors:  Aoife Maguire; Edi Brogi
Journal:  Histopathology       Date:  2016-01       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.